News : Diamyd

Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company’s patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy. The grant allows Diamyd to expand the NTDDS technology to also target neuropathy, in addition to the Company’s development portfolio for the treatment of...

As of April 30, 2010, the share capital in Diamyd Medical AB (publ.) is 14,500,052.5 SEK. The total number of votes is 4,194,099 and the total number of shares is 29,000,105, divided among 1,437,876 shares of series A (1 vote) and 27,562,229 shares of series B (1/10 vote).

The change is due to a direct placement of new shares. The Board of Diamyd decided on the new issue based on the authorization given by the...

In her comments in today’s quarterly report, Elisabeth Lindner, President and CEO of Diamyd Medical, describes the progress in the decisive Phase III studies with the Company’s lead drug candidate Diamyd®, and comments on the Company’s strategies and efforts to build a Nordic specialty pharmaceutical company.
”We have exciting times ahead of us with only one year to go before we have the results from our...

Quarterly report, Stockholm, April 28, 2010
September 1, 2009 - February 28, 2010

Second quarter report for Diamyd Medical AB (publ), fiscal year 2009/2010
(www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY


Second quarter December 1, 2009 – February 28, 2010
- Group net sales for the second quarter was MSEK 0.2 (0.8)
- Loss before tax for the second quarter was MSEK -26.6 (-15.4)
- Earnings per share...

Diamyd Medical has accepted an offer from an investment fund managed from New York by a Swedish-American team to issue 291,667 new B shares in a direct placement at 120 SEK per share. The issue price corresponds to the average market price of the past 30 trading days. Total proceeds for Diamyd amounts to 35 MSEK.
“We welcome an additional investor with a long term horizon to our list of major shareholders,”...

The FDA has granted Orphan Drug Designation of Diamyd Medical´s lead drug candidate Diamyd®. Orphan drugs qualify for seven years of market exclusivity from the date of US marketing approval, tax credits for clinical research and a waiver for FDA user fees.
“This is extremely good news that we finally received today”, says Elisabeth Lindner, CEO and President of Diamyd Medical. “The granted Orphan Designation...

Due to increased turnover in the share Mangold Fondkommission AB will no longer act as liquidity provider in Diamyd Medical’s B-share. The current liquidity provider agreement will expire on March 5, 2010. A new liquidity provider has not been appointed.

The shareholders of Diamyd Medical AB (publ) are summoned to the Annual General Meeting on Friday December 11, 2009 at 3:00 p.m. at the IVA Conference Center, Grev Turegatan 16 (Wallenberg auditorium) in Stockholm.
Under item 11 in the agenda, Diamyd’s Nomination Committee now proposes that an additional Director is elected to the Board of Directors.
The Nomination Committee proposes that Göran Pettersson is...